Metformina + Vildagliptina Pentafarma

Metformin hydrochloride, the active ingredient in Metformina + Vildagliptina Pentafarma, is a biguanide presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adult patients by improving glycemic control. GNH USA supplies Metformina + Vildagliptina Pentafarma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformina + Vildagliptina Pentafarma is used in the management of type 2 diabetes mellitus, a chronic metabolic disorder requiring long‑term glucose‑lowering therapy. - Type 2 diabetes mellitus: improves overall glycemic control when added to diet and exercise. - Inadequate control on metformin alone: provides additional glucose‑lowering effect through DPP‑4 inhibition. - Patients needing combination therapy: simplifies regimen by combining a biguanide with a DPP‑4 inhibitor in a single tablet.

The most frequently reported reactions are mild and reversible.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, often transient. - Abdominal discomfort: cramping or pain. - Headache: mild tension‑type headache. - Dizziness: light‑headed sensation. - Metallic taste: altered taste perception.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic disturbance. - Severe hypoglycaemia: especially when combined with insulin or sulfonylureas. - Acute pancreatitis: sudden abdominal pain with elevated enzymes. - Hepatic failure: marked liver enzyme elevation. - Anaphylactic reaction: severe allergic response requiring emergency care.

Metformina + Vildagliptina Pentafarma requires careful patient assessment before initiation. - Renal function: assess eGFR; avoid in severe renal impairment. - Hepatic disease: use with caution; monitor liver enzymes. - Lactic acidosis risk: discontinue if patient develops hypoxia, sepsis, or acute heart failure. - Concomitant hypoglycaemic agents: monitor for low blood glucose. - Pregnancy and lactation: safety not established; weigh benefits against risks. - Store at ambient temperature: keep in original container, protect from moisture and heat.

Drug‑drug interactions may affect efficacy or safety of Metformina + Vildagliptina Pentafarma.

Major Interactions (Avoid): - Severe renal failure: increased risk of metformin accumulation. - Hepatic failure: heightened lactic acidosis potential. - Alcohol abuse: potentiates metformin‑related lactic acidosis. - Concurrent use of other biguanides: additive risk of toxicity. - Iodinated contrast agents: may precipitate acute renal injury.

Moderate Interactions (Monitor Closely): - Sulfonylureas or insulin: increased hypoglycaemia risk. - Diuretics (especially thiazides): may reduce renal clearance. - ACE inhibitors or ARBs: monitor renal function and electrolytes. - Beta‑blockers: may mask hypoglycaemia symptoms. - CYP450‑modulating drugs: observe for altered vildagliptin levels.